Influence of serum ferritin combined with blood cadmium concentrations on blood pressure and hypertension: From the Korean National Health and Nutrition Examination Survey

Chemosphere ◽  
2022 ◽  
Vol 288 ◽  
pp. 132469
Author(s):  
Jeoung A. Kwon ◽  
Eunjung Park ◽  
Seyoung Kim ◽  
Byungmi Kim
Keyword(s):  
Blood Pressure ◽  
Serum Ferritin ◽  
National Health ◽  
Nutrition Examination Survey ◽  
Health And Nutrition ◽  
Blood Cadmium

scholarly journals The association between serum copper concentrations and elevated blood pressure in US children and adolescents: National Health and Nutrition Examination Survey 2011–2016

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Changsong Liu ◽  
Yanfen Liao ◽  
Zongyuan Zhu ◽  
Lili Yang ◽  
Qin Zhang ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Children And Adolescents ◽  
National Health ◽  
Serum Copper ◽  
Elevated Blood Pressure ◽  
Nutrition Examination Survey ◽  
Elevated Blood ◽  
Cross Sectional ◽  
Health And Nutrition ◽  
Us Children

Abstract Background Copper is an essential trace metal with potential interest for cardiovascular effects. Few studies have explored the association between copper and blood pressure in children and adolescents. Method We conducted a cross-sectional analysis of 1242 children and adolescents aged 8–17 years who participated in the 2011 to 2016 National Health and Nutrition Examination Survey. Using 2017 American Academy of Pediatrics guidelines, elevated blood pressure (EBP) was defined as a mean systolic and/or diastolic blood pressure (BP) ≥ 90th percentile for sex, age, and height for children aged 1–12 years and systolic BP ≥ 120 mmHg or diastolic BP ≥ 80 mmHg for adolescent age 13–17 years. Mean serum copper was 114.17 μg/dL. Results After multiple adjustments, dose–response analyses revealed that EBP was associated with progressively higher serum copper concentrations in a nonlinear trend. In comparison with the lowest quartile of serum copper concentrations, the adjusted odds of EBP for the highest quartile was 5.26 (95% confidence interval, 2.76–10.03). Conclusion Our results suggested that high serum copper concentrations were significantly associated with EBP in US children and adolescents.

scholarly journals A data-zone scoring system to assess the generalizability of clinical trial results to individual patients

2018 ◽  
Vol 26 (6) ◽  
pp. 569-575 ◽  
Author(s):  
Luke J Laffin ◽  
Stephanie A Besser ◽  
Francis J Alenghat
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
National Health ◽  
Hazard Ratio ◽  
Trial Participant ◽  
Nutrition Examination Survey ◽  
Specific Patient ◽  
Health And Nutrition ◽  
Baseline Characteristics ◽  
Event Rates

Introduction Evaluating the applicability of a clinical trial to a specific patient is difficult. A novel framework, the Trial Score, was created to quantify the generalizability of a trial's result based on participants' baseline characteristics and not on the trial's inclusion and exclusion criteria. Methods For each Systolic Blood Pressure Intervention Trial (SPRINT) participant, the Euclidean distance in six-dimensional space from the theoretical “average” participant was calculated to produce an individual Trial Score that incorporates multiple distinct continuous-variable baseline characteristics. We prospectively defined the “data-rich,” “data-limited,” and “data-free” zones as Trial Scores < 90th percentile, the 90th–97.5th percentile, and >97.5th percentile, respectively. Trial Scores were then calculated for National Health and Nutrition Examination Survey participants to map data zones of the general population. Individual participant data from the Action to Control Cardiovascular Risk in Diabetes blood pressure trial (ACCORD-BP) was used to test if participants further from the average SPRINT participant behave differently than the overall SPRINT results. Results The National Health and Nutrition Examination Survey cohort and the ACCORD-BP trial demonstrate large percentages of participants in SPRINT's data-free and data-limited zones. Time-to-event rates seen with intensive and standard blood pressure control in SPRINT were the same as ACCORD-BP participants within SPRINT's data-rich zone (hazard ratio 0.97, p = 0.84 and hazard ratio 0.95, p = 0.70). However, these rates were significantly different than those of ACCORD-BP participants outside SPRINT's data-rich zone (hazard ratio 0.64, p < 0.01 and hazard ratio 0.77, p < 0.01). Conclusions ACCORD-BP participants with SPRINT Trial Scores in the 90th percentile or below have similar event rates to SPRINT participants in both the intensive and standard blood pressure groups. Quantifying the difference between an individual patient and the average clinical trial participant holds promise as a tool to more precisely determine applicability of a specific trial to individual patients.

Sign in / Sign up

Export Citation Format

Share Document